Despite remarkable progress in the treatment of hepatitis C virus (HCV) infection, it remains
a significant global health burden, necessitating the development of an effective prophylactic …

During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic,
multiple variants escaping preexisting immunity emerged, causing reinfections of previously …

Despite the recent development of safe and highly effective direct-acting antivirals, hepatitis
C virus (HCV) infection remains a significant health problem. In 2016, the World Health …

Hepatitis C virus (HCV) infection affects approximately 58 million people and causes~
300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly …

Hepatitis C virus (HCV) is a major global health burden as the leading causative agent of
chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV …

A paradigm of RNA viruses is their ability to mutate and escape from herd immunity.
Because antibody responses are a major effector for viral immunity, antigenic sites are …

T cell exhaustion is a hallmark of hepatitis C virus (HCV) infection and limits protective
immunity in chronic viral infections and cancer. Limited knowledge exists of the initial viral …

The increasing incidence of hepatitis C virus (HCV) infections underscores the need for an
effective vaccine. Successful vaccines to other viruses generally depend on a long-lasting …

A functional adaptive immune response is the major determinant for clearance of hepatitis C
virus (HCV) infection. However, in the majority of patients, this response fails and persistent …

Hepatitis C virus (HCV) is a major worldwide health burden, and a preventive vaccine is
needed for global control or eradication of this virus. A substantial hurdle to an effective HCV …